Yelena Novik, MD

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the benefits and challenges of the global implementation of biosimilars.

Yelena Novik, MD, associate professor, NYU Langone’s Perlmutter Cancer Center, discusses CDK4/6 inhibitor combinations in breast cancer.

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the potential impact of biosimilars on the treatment of cancer.

Yelena Novik, MD, associate professor, New York University Langone’s Perlmutter Cancer Center, discusses the sustainability of drug development in oncology.

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.